<< Вернуться к списку статей журнала

Том 1 №1 1999 год - Нефрология и диализ

Отдаленные результаты трансплантации почки и факторы риска хронической нефропатии отторжения

Ким И. Г. Стенина И. И. Ильинский И. М. Томилина Н. А.

Аннотация: Изучены отдаленные результаты первичной аллотрансплантации трупной почки (АТП) и факторы риска хронического отторжения (ХОТ) на материале наблюдений 232 реципиентов аллогенной почки, оперированных в НИИТ и ИО в период с января 1989 г. по январь 1993 г. и прослеженных не менее 12 мес. после операции. Отдаленные результаты АТП оценивались по выживаемости трансплантатов и периоду полужизни, а факторы риска ХОТ - по актуариальной функциональной выживаемости (АФВ), под которой понимали долю трансплантатов, обеспечивавших нормальный уровень креатинина плазмы крови. Выживаемость трансплантатов через 5 лет после операции составила 57%, период полужизни - 8,1 г. Наиболее частой (в 59% случаев) причиной прекращения функции ренального аллотрансплантата (PAT) было ХОТ. В многофакторной регрессионной модели Кокса выявилась значимая связь ХОТ с антиген-зависимыми (кризы отторжения, адекватность иммуносупрессии) и неспецифическими факторами (уменьшение массы действующих нефронов PAT к 6 мес. после операции, артериальная гипертензия и протеинурия). 5-летняя АФВ PAT при течении без кризов была равна 54%, после 1 криза отторжения - 40%, после повторных кризов - 18%. Отрицательное прогностическое значение имело неполное восстановление функции после криза. Последнее тесно коррелировало с дисфункцией PAT через 6 мес. после АТП. Неадекватность иммуносупрессии констатирована в случаях недостаточной дозировки циклоспорина А и/или отмены азатиоприна. 5-летняя АФВ PAT снижалась при этом на 43% и 27% соответственно. Повышение АД и степень артериальной гипертензии (АГ) значимо коррелировали с АФВ PAT, которая снижалась на 21% при умеренной и на 35% - при выраженной АГ. Последняя была тесно связана с протеинурией, но выступала при этом как независимый фактор. Полученные данные позволяют также считать, что оба указанных синдрома являются ранними предикторами ХОТ.

Для цитирования: Ким И. Г., Стенина И. И., Ильинский И. М., Томилина Н. А. Отдаленные результаты трансплантации почки и факторы риска хронической нефропатии отторжения. Нефрология и диализ. 1999. 1(1):49-68. doi:

Весь текст

Ключевые слова: трансплантированная почка, отдаленные результаты, хроническое отторжение, антиген-зависимые и неспецифические факторы риска, артериальная гипертензия, протеинурия

Список литературы:

1. Белорусов О.С., Горяйнов В.А. Некоторые аспекты аллотрансплантации почек от живых родственных доноров. Трансплантология и искусственные органы 1997; №4: 60-63.
2. Белорусов О.С., Горяйнов В.А., Егорова И.А. Опыт применения иммуносупрессанта сандиммуна (циклоспорина А) при трансплантации почек в клинике. Хирургия 1986; №3: 20-24.
3. Бирюкова Л.С. Осморегулирующая функция аллотрансплантированной почки и некоторые механизмы ее нарушения на разных этапах посттрансплантационного периода. Автореф. дис. канд. мед. наук. М. 1988; 25 стр.
4. Ватазин А.В., Пасов С.А., Щербакова Е.О., и др. Применение циклоспорина А у больных после пересадки трупной почки Трансплантология и искусственные органы 1998; №1: 3-8.
5. Ратнер М.Я. Оценка почечных функций и классификация их расстройств при заболевании почек. В кн.: Ратнер М.Я, Серов В.В., Томилина Н.А. Ренальные дисфункции. Медицина, М. 1977; стр. 32-42.
6. Столяревич Е.С., Ильинский И.М., Варшавский В.А., и др. Факторы прогрессирования хронической нефропатии отторжения: клинико-морфологический анализ. Нефрология 1998; №2:45-51.
7. Томилина Н.А. Нефропатия отторжения (диагностика, клинические варианты течения, антикоагулянтно-антиагрегантная терапия). Автореф. дис. докт. мед. наук. М. 1988; 25 стр.
8. Томилина Н.А. Расстройства функций почечного аллотрансплантата. В кн.: Ратнер М.Я., Серов В.В., Томилина Н.Д. Ренальные дисфункции. Медицина, М. 1977; стр. 221-250.
9. Томилина Н.А. Механизмы прогрессирования хронической почечной недостаточности. Сборник материалов международного нефрологического симпозиума М 1988; стр.7-13.
10. Тареев Е.М. Нефриты. Медицина. М. 1958; стр. 239-240.
11. Шумаков В.И., Левицкий Э.Р., Порядин Н.Ф. Синдром отторжения при трансплантации почки. Медицина, М. 1982; стр.106-107,190-191.
12. Шумаков В.И., Мойсюк Я.Г., Томилина Н.А., Ермакова И.П. Трансплантация почки. В кн.: Шумаков В.И., ред. Трансплантология. Медицина, М. 1995; стр. 194-196.
13. Albrechtsen D., Berg R.J., Rugstad H.E., et al. Blood and Plasma Cyclosporine Levels in Renal Transplantation. Transplant Proc 1986; 18:44-46.
14. Amenabar J.J., Gomez-Ullate P., Garcia-Lopez F.J., et al. A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation. Transplantation 1998; 65:653-661.
15. Almond H.S., Matas A., Gillingham K., et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752-757.
16. Basadonna G.P., Matas A.J., et al. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993; 55:993-995.
17. Barnas V. and Mayer G. Glomerular proteinuria in renal transplant patients: mechanisms and treatment. Kidney Int 1997; 52: ( Suppi. 63) 78-80.
18. Beik А.I., Higgins R.M., Lam F.T. and Morris A.G. Steroid withdrawal and donor-specific hyhoreactivity after cadaveric renal allotransplantation on maintenance triple therapy. Nephrol Dial Transplant 1997; 12:1949-1955.
19. Berloco P., Alfani D., Famulari A., et al. Utilization of Living Donor Organs for Clinical Transplantation. Transplant Proc 1985; 17: 13-17.
20. Bia M.J., Raamos E.L., Danovitch M., et al. Evaluation of living renal donors. Transplantation 1995; 60: 322-327.
21. Borchhardt К., Haas М., Yilmas N., Mayer G., et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52: 1622-1625.
22. Brenner B.M., Milford E.L. Nefron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21:66-72.
23. Brenner B.M. and Mackenzie H.S. Nephron endowment and pathogenesis of chronic renal failure. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp.93-100.
24. Briggs J.D. and B.J.R. Junor. Long-term results and complications. In: Davison A.M., CameronJ.S., GrunfeidJ-P. et al. eds., Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, New York, Tokyo 1998. Vol.3: pp. 2177-2204.
25. Bock Н.А. Chronic rejection and hypertension: a chicken-and-egg problem. Editional Comments. Nephrol Dial Transplant 1995; 10:1126-1128.
26. Busson M., Prevost P., Bignon J.D., et al. Multifactorial analysis of the outcome of 6430 cadaver kidney grafts. Transplant Int 1992; 5:162-164.
27. Chapman J.R. Changing the regimen. Nephrol Dial Transplant 1995; 10: (Suppi 1) 51-57.
28. Chapman J.R., Alien R.B., Ekberg H. Elective CyA conversion from triple therapy. Transplant Proc 1989; 21: 1631-1632.
29. Chertow G.M., Brenner B.M., Mackenzie H.S. and Milford E.L. Non-immunologic predictors of chronic renal allograft failure: Date from the United Network of Organ Sharing. Kidney Int 1995; 48:48-51.
30. Chertow G.M., Brenner B.M., Mori M., Mackenzie H.S., Milford E.L. Antigen - independent determinants of graft survival ii living-related kidney transplantation. Kidney Int 1997; 52: (Suppi 6?) 84-86.
31. Cecka J.M., Terasaki P.I. The UNOS Scientific Renal Transplant Registry. In: Cecka J.M., Terasaki P.I., eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Laboratory; 1996: pp. I-18.
32. Cecka J.M., Terasaki Р.I. Early rejection episodes In: Terasati P.I. ed. Clinical Transplants 1989. Los Angeles UCLA Tissue Laboratory; 1989: pp. 425-434.
33. Curtis J.J. Treatment of hypertension in renal allograft patients: Does drug selection make a difference? Kidney Int 1997; 52: 75-77.
34. Cosio F.G., Pelletier R.P., Falkenhain M.E., et al. Impact of acute rejection and ealy allograft function on renal allograft survival Transplantation 1997; 63:1611-1615.
35. Dunn J., Golden D., C.T. van Buren, Levis R.M., Laven J. and Kahan B.D. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349-353.
36. Dunn J., Grevel J., Napoli K., et al. The impact of steady-state cyclosporine concentrations on renal allograft outcome Transplantation 1990; 49:30-34.
37. Fellstrom В., Backman U., et al. Transplantation atherosclerosis: Definition and pathogenesis. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp. 38 48.
38. Flechner S.M., C.S. Modlin, D.P. Serrano, D.A. Goldfarb, D. Papajclk, B. Mastroianni, M. Goormastic and A.C. Novick. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996; 62: 1235-1241.
39. First M.R. Renal allograft survival after I and 10 years: corn parisone between precyclosporine and cyclosporine data. Nephrol Dial Transplant 1994; 9: 90-97.
40. First M.R., Vaidya P.N., et al. Proteinuria following transplantation. Transplantation 1984; 38:607-612.
41. Gelder Т., Klassen R.J.L. et al. Mycophenolate mofetil and prednisolone as maintenance treatment after kidney transplantation. Transplantation 1997; 63:1530-1531.
42. Gjertson D.W. Survival trends in long-term first cadavel-donor kidney transplants. In: Cecka J.M., Terasaki P.I. eds. Clinical transplants. Los Angeles 1992: pp. 225-235.
43. Gjertson D.W., Cecka J.M., Terasaki P.I. The relative effects of FK 506 and cyclosporin on short- and long-term kidney graft survival. Transplantation 1995; 60:1384-1388.
44. Grinyo J.M., S.Gil-Vernet, Moreso F., et al. Ischemia-reperfusion injury as a risk factor for late kidney graft failure. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp.77-83.
45. Hardie L., Strong R., Wall D., et al. Results of 1000 Kidney Transplants in Brisbane. Transplant Proc 1989; 21: (Suppl.5) 3775-3776.
46. HeldermanJ.H. and Goral S. Cyclosporin withdrawal: to be or not to be! Nephrol Dial Transplant 1998; 13: 31-33.
47. Hollander A.A.M.J., Saase J.L.C.M van, Kootte A.M., et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 1995; 22: 610-614.
48. Hoistma A.J., van Lier H.J.J., Wetzels J.F.M., Berdti J.H.M., Koene R.A.P. Cyclosporine treatment with conversion ate three months versus conventional immunosupression in renal allograft recipients. Lancet 1987; 14: 584-586.
49. Hong J.H., Sumrany N., Delaney V., et al. Causes of Late Renal Allograft Failure in the Cyclosporin Era. Nephron 1992; 62: 272-279.
50. Hiesse С., Neyret N., Deglise-Favre A., et al. Randomised prospective trial of elective cyclosporine withdrawal from triple therapy at 6 months after cadaveric renal transplantation. Transplant Proc 1991; 23:987-988.
51. Hostetter Т.Н. Chronic transplant rejection. Kidney Int 1994; 46:266-279.
52. Isoniemi H., Lehtonen S., Salmela K., Ahonen J. Does delayed kidney graft function increase the risk of chronic rejection? Transplant Int 1996; 9: ( Suppl.1) 5-7.
53. Isoniemi H.M., Ahonen J., Tikkanen MJ., et al. Long-term consequences of different immunosupressive regimens for renal allografts. Transplantation 1993; 55: 494-499.
54. Johnson R.W.G. Primary regimens in immunosuppression. Nephrol Dial Transplant 1995; 10: (Suppl.1) 161-164.
55. Jeroms G., Panagiotopoulos S., et al. Why proteinuria such an important risk factor for progression in clinical trials? Kidney Int 1997; 52: (Suppl.63) 87-92.
56. Kahan B.D. and Grevel J. Optimization ofcyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46:631-644.
57. Kahan B.D. Summary on Therapeutic Drug Monitoring for Renal Transplantation. Transplant. Proc. 1990; 22: 1348-1351.
58. Kahan B.D. Pharmacokinetics of cyclosporin formulations and their relationship to clinical outcome. Focus on medicine 1998; N 13:3-6.
59. Kaplan N.M. Clinical Hypertension 1998: 181-273.
60. Kasiske B.L. Clinical correlates to chronic renal allograft rejection Kidney Int 1997; 52: (Suppl.63) 71-74.
61. Kasiske B.L., Heim-Duthoy К., Ma J.Z. Elective Cyclosporine Withdrawal after Renal Transplantation: A Meta-Analisis.JAMA 1993; 269 (3): 395-400.
62. Kasiske B.L., Kalil R.S.N., Lee H.S., et al. Histopathfinding associated with chronic progressive decline in renal allograft function. Kidney Int 1991; 40: 514-524.
63. Kliem V., Tiroke Т., Ehlerding G., et al. Long-term benefit of additional azathioprine in cyclosporine/prednisolone-treated patients with chronic renal allograft dysfunction. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp. 195-198.
64. Kootte A.M.M., Lensen L.M., van Es L.A., and Paul L.S. Controlled cyclosporine conversion at three month after renal transplantation. Transplantation 1988; 46:677-680.
65. Koning O.H.J., Ploeg RJ., J.H. van Bockel, et al. Risk factors for delayed graft function in cadaveric kidney transplantation. Transplantation 1997; 63:1620-1628.
66. Kunz R. and Neumayr H.H. Maintenance therapy with triple versus double immunosupressive regimen in renal transplantation. Transplantation 1997; 63:386-392.
67. Leggat J.E., Ojo A.O., Leichtman A.B., Port F.K., et al. Long-term renal allograft survival. Transplantation 1997; 63: 1268-1272.
68. Lennard T.W., Venning M., Donnely P.K. et al. Conversion of immunosupression in renal allograft recipients from CsA to Aza and prednisolone 6 months after transplantation. Transplant Proc 1987; 20:3594-3596.
69. Lindholm A., Ohlmfn S. et al. The impact of acute rejection episodes on long-term graft function and out-come in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56:307-315.
70. Mackenzie H.S., Azurna H., Rennke H.G. et al. Renal mass as a determinant of late allograft outcome: Insights from experimental studies in rats. Kidney Int 1995; 48: 538-542.
71. Mahony J.F. Long Term Results and Complications of Transplantation: The Kidney. Transplant Proc 1989; 21: 1433-1434.
72. Massy Z.A., Guljarro С. and Kasiske B.L. Clinical predictors of chronic renal allograft rejection. Kidney Int 1995; 48: 85-88.
73. Massy Z.A., Guijarro С. et al. Chronic renal allograft rejection: Immunjlogic and nonimmunologic risk factors. Kidney Int 1996; 49:518-524.
74. Matas A.J., GilUngham K.J., Payne W.D., NajarianJ.S. The impact of an acute rejection episode on long-term renal allograft survival Т1/2. Transplantation 1994; 57: 857-860.
75. Matas A.J., Gillingham KJ., Sutherland D.E.R. Half-life and risk factors for kidney transplant outcome-importance of death with function. Transplantation 1993; 55: 757-761.
76. Mayer D., Dmitrevski J., Squifflet J.-P. et al. Multicenter randomized trial comparing tacrolimus (FK 506) and cyclosporine in the prevention of renal allograft rejection. Transplantation- 1997; 64: 436-443.
77. Montagnino G., Tarantino A., Banfi G. et al. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation. Transplantation 1994; 58:149-154.
78. Morris RJ. Transplantat immunology. In: Davison A.M., Cameron J.S., Grunfeld J-P. et al., eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, New York, Tokyo 1998; Vol.3: pp. 2137-2145.
79. Morris P. J., Alien R.D., Thompson J.F., Chapman J.R., Ting A., Wood R.F.M. Cyclosporine conversion versus conventional immunosupression: long-term follow-up and histological evaluation. Lancet 1987; 14:586-591.
80. Mihatsch M.J., Riffel В., and Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995;48: (Suppl.52) 63-69.
81. Nahas A.M.E. Mechanisms of experimental and clinical renal scarring. In: Davison A.M., Cameron J.S., Grunfeld J-P. et al., eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, New York, Tokyo 1998; Vol.3: pp. 1749-1776.
82. Najarian J.S., Gillingham K.J. et al. The impact of quality of initial graft function on cadaver kidney transplants. Transplantation 1994; 57:812-816.
83. Nankivell B.J., Allan R.D.M., O'Connell P.J., and Chapman J.R. Renal dysfunction in acute rejection. Transplantation 1995; 60:28-36.
84. Neugarten J. and Silbiger S.R. The impact of gender on renal transplantation. Transplantation 1994; 58: 1145-1152.
85. Newstead C.G., Johnston PA., Will E.J., and Davison A.M. The case for withdrawal of cyclosporin after renal transplantation. Nephrol Dial Transplant 1998113: 28-31.
86. Nicol D., MacDonald A.S., Lawen J., Belitsky P. Early prediction of renal allograft loss beyond one year. Transplantation 1993; 6:153-157.
87. Ojo A.O., Wolfe R.A., Held P.J., Port F.K. and Schmouder R.L. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974.
88. Opelz G. For the Collaborative Transplant Study. Collaborative Transplant Study- IO-year report. Transplant Proc 1992;24: 2342-2355.
89. Opelz G. Effect of maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-446.
90. Opelz G. Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. Kidney Int 1995; 48 (Suppi. 52) 89-92.
91. Opelz G., Wujciak Т. and Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217-222.
92. Opelz G. for the Collaborative Transplant Study. Chronic graft loss in kidney and heart transplant recipients. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; рр.З-12.
93. Opelz G. For the Collaborative Transplant Study. Newsletter 3 1998; 5 ps.
94. Paraiso A.R., Ona E.T., Alano F.A., Ramos C.P. and Luna M. Immunosupressive conversion from CyA to Aza in renal transplant patients. Transplant Proc 1989; 21: 1627.
95. Paredes D., Sola R. et al. Effect of angiotensin convetrting enzyme inhibitors (ACEI) on the progressive graft failure and proteinuria in kidney transplant patients with chronic rejection. In: Touraine J.L., Traeger J„ Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; PP.197-198.
96. Paul L.C. and Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995; 48: 34-37.
97. Paul L.C., Muralidharan et al. Immunological mechanism of chronic rejection. In: Touraine J.L., Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp.51-6l.
98. Paul L.C. Chronic renal transplant loss. Kidney Int 1995; 47: 1491-1499.
99. Pedersen E.B., Hansen H.E., Komenip H.J. et al. Long-term Graft Survival after Conversion from Cyclosporine to Azathioprine I Year after Renal Transplantation. Nephrol Dial Transplant 1993; 8:250-254.
100. Pirsch J.D. Effect of new immunosupressive drugs on chronic rejection. In: Touraine J.L.,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp.l27-133.
101. Pirsch J.D., Ploeg R.J., Gange S. et al. Determinants of graft survival after renal transplantation. Transplantation 1996; 61: 1581-1586.
102. Pirsch J.D., Allessandro A.M., Sollinger H.W. et al. The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients. Transplantation 1992; 53: 55-59
103. Peeters J. Roels Land Vanrenterghem. Chronic renal allograft failure: Clinical overview. Kidney Int 1995; 48 (Suppl.52) 97-101.
104. Ponticelli С. and Tarantino A. Immunosupressive protocols for renal transplantation. Nephrol Dial Transplant 1997;12:45-50.
105. Raine A.E.G. Hypertension and ischaemic heat disease in renal transplant recipients. Nephrol Dial Transplant 1995;10: (SuppLI) 95-100.
106. Remuzzi G. and Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules ? Kidney Int 1990; 38: 384-394.
107. Ritz E. Hypertonie und Niere. Arzneim.-Forsch. Drug Res 1997; 47 (11): 1297-1301.
108. Russ G.R. Immunosupression in transplantation. The medical J Australia 1992; 157:198-203.
109. Salvatierra O. Advantages of Continued Use of Kidney Transplantation From Living Donors. Transplant Proc 1985; 17: 18-22.
110. Sanders C.E., Jr. and J.J. Curtis. Role of hypertension in renal allograft dysfunction. Kidney Int 1995; 48: (Suppl.52) 43-47.
111. Savodi S., Maiorica R., Maderna R. et al. Low intrapatient variability of blood cyclosporin levels is correleted with excellent graft survival. Transplant Proc 1997; 29: 288-289.
112. Seron D., Moreso F., Bover J. et al. Evaluation of biopsy changes in early diagnosis of chronic transplant nephropathy. In: Touraine J.L, Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; pp.25-30.
113. Shaw L.M., Audet P.R. et al. Adjustment of Cyclosporine Dosage in Renal Transplant Patients Based on Concetration Measured Specifically in Whole Blood: Clinical outcome Results and Diagnostic Utiliti. Transplant Proc 1990; 22: 1267-1275.
114. Shen S.Y. and Weir M.R. Renal allograft biopsy and conversion ofCsA to Aza. Transplantation 1989; 47: 223-229.
115. Sibley К. Histopathology of chronic rejection. In: Touraine J.L,Traeger J., Betuel H. et al., eds. Late graft loss. Dordrecht, Boston, London 1997; PP.13-23.
116. Smith S.R., Minda S.A., Samsa G.P. et al. Late Withdrawal of Cyclosporine in Stable Renal Transplant Recipients. Am J Kidney Dis 1995; 487-494.
117. Sollinger H.W. for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 58:225-232.
118. Soles К., Axelsen RA, Benediktsson H. et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411-422.
119. Soles К. Renal allograft histopathology. Nephrol Dial Transplant 1995; 10:44-50.
120. SPSS Advanced Statistics 7.5. 1997; рр.285-310.
121. Strom T.V. and Suthanthrian M. Therapeutic approach to renal transplantation. In: Davison AM., Cameron J.S., Grunfeld J-P. et al., eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, New York, Tokyo 1998; Vol.3: pp. 2147-2151.
122. Striker L.J. Nephron reduction in man- lessions from the 0s mouse. Nephrol Dial Transplant 1998; 13: 543-545.
123. Sutherland F., Burgess E., Klassen J. et al. Post-transplant Conversion from Cyclosporine to Azathioprine: Effect on Cardiovascular Risk Profile. Transplant Int 1993; 6:129-132.
124. Sumrani N., Cacclarelll T.V. et al. Contribution of acute rejection to renal allograft loss from chronic rejection. Transplant Proc 1993; 25: 2259-2260.
125. Takiff H., Cook D.J. et al. Dominant effect of histocompalibility on ten-year kydney transplant survival. Transplant 1988; 45: 410-415.
126. Tenzess A. M., Son W. L., Maar E.F. Elective conversion from CyA to Aza and prednisolone in patients after cadaver renal transplantation. Transplant Proc 1989; 21: 1635-1637.
127. Terasaki Р.L., Cecka J.M., Gjertson et al. A ten year pre diction for kidney transplant survival. In: Terasaki P.I., Cecka J.M., eds. Clinical Transplants 1992; pp. 501-512.
128. Terasaki P.L, Cecka J.M., Gjertson et al. High survival rates of kidney trasplants from spousal and living unrelated donors. The New England Journal of Medicine 1995; 333-336.
129. Tesi R.J., Henry M.L. et al. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993; 7: 345.
130. Thorogood J., Van HouweUngenJ.C.,Perslng G.G. et i\. Prognostic indices to predict survival of first and second renal alto-grafts. Transplantation 1991; 52:831-836.
131. Thorogood J., Van Houwelingen J.C., Van Rood J.J. et al. Factors Contributing to Long- Term Kidney Graft Survival in Eurotransplantat. Transplantation 1992; 54(1): 152-158.
132. Touchard G., Hauet T. et al. Maintenance cyclosporin monotherapy after renal transplantation- clinical predictors of long-term outcome. Nephrol Dial Transplant 1997; 12: 1956-1960.
133. Traindi O., Falger S., Reading S., Kovarik J. et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309-1313.
134. 1The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029-1037.
135. Troppmann C., Gillingham K.J. Matas A.J. et al. Delayed graft function in the absence of rejection has no long-term impact. Transplantation 1996; 61:1331-1337.
136. Vanrenterghem Y.F.C. Acute rejection and renal allograft out-come. Nephrol Dial Transplant 1995; 10: (Suppl.l) 29-31.
137. Vanrenterghem Y.F.C. Impact of new immunosuppressive agents on late graft outcome. Kidney Int 1997; 52: (Suppl.63) 81-83.
138. Vanrenterghem Y.F.C. and Peeters J. for the Leuveii Collaborative Group for Transplantation. The impact of acute rejection in the longterm outcome after renal transplantation. In: Touraine J.L,Traeger J., Betuel H. et aL, eds. Late graft loss. Dordrecht, Boston, London 1997; PP.85-89.
139. Venning M.C., Lennard T.W., Stenens M. E. and Proud G. CsA treatment with successful conversion after 6 months in 70 renal allograft recipients. Transplant Proc 1989; 21:1633-1634.
140. Watsn M.A., Briggs J.D., Junor B.J.R., McMilan M.A., Macplerson S.G., Murray G. and Stewart. Randomised trial of conversion from cyclosporine to at one year after renal transplanta. tion. Transplant Proc 1989; 21:1583-1584.
141. Weber M. and Candinas D. Immunologic maching between donor and recipient for solid organ transplantation. Current Opinion in Organ Transplantation 1997; 62:151-156.
142. Woodle E.S., Thomas G., Heffron T.G., Stuart J.K, Thistiethwait J.R. and Stuart F.P. Effect of discontinuing oi restricting cyclosporine on late renal allograft rejection and function. Transplant Proc 1989; 21: 1641-1642.
143. Yilmas S., Hayry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografis. Transplantation 1993; 56:1153-1156.

Другие статьи по теме

• Влияние дисбаланса плацентарных факторов ангиогенеза на клинические проявления «ранней» и «своевременной» преэклампсии
• Результаты сплошного скрининга по раннему выявлению хронической болезни почек у жителей г. Алматы
• Факторы риска неблагоприятного исхода гемолитико-уремического синдрома у детей
• Семейный транстиретиновый амилоидоз: мини-обзор и описание трех случаев среди членов одной семьи